uniQure N.V.

-0.83 (-4.77%)
Products, Regulatory

Uniqure Announces Clinical Update On First Patients In Phase I/II Clinical Trial Of Amt-130 Gene Therapy For The Treatment Of Huntington’S Disease

Published: 12/16/2021 12:51 GMT
uniQure N.V. (QURE) - Uniqure Announces Clinical Update on First Patients in Phase I/ii Clinical Trial of Amt-130 Gene Therapy for the Treatment of Huntington’s Disease.
Uniqure NV - Treatment Was Well Tolerated With No Significant Safety Issues Related to Amt-130 in First 2 Treated Patients Through One Year of Follow-up.
Uniqure NV - Higher-dose Cohort Enrollment Expected to Be Completed by Mid-2022.
Uniqure NV - Screening Initiated in European Open-label Phase I/ii Study.
Uniqure NV - Clinical Update on Low-dose Cohort of Ten Patients, Largely Focused on Safety, is Expected in Q2 of 2022 After Patient Unblinding.
Uniqure NV - Full Safety and Efficacy Data From First Two Cohorts in Phase I/ii Clinical Trial Are Expected in First Half of 2023.